Indolent Lymphoma
Conference Coverage
Novel options for treating hairy cell leukemia
NEW YORK –
Conference Coverage
Real-world clues for optimal sequencing of CLL novel agents
NEW YORK – Dr. John Allan of Cornell University said
News
FDA approves new drug for CLL/SLL and follicular lymphoma
Duvelisib (Copiktra) has full approval to treat CLL/SLL and accelerated approval to treat FL.
From the Journals
Be wary of watchful waiting in follicular lymphoma
Management changes may be warranted.
From the Journals
Pruritus linked to wide variety of cancers
The odds of specific cancers vary by race.
Guidelines
ASCO updates guidance on prophylaxis for adults with cancer-related immunosuppression
Fluoroquinolones are recommended for adults with cancer-related immunosuppression if they are at high risk of infection, according to an updated...
From the Journals
Rituximab/lenalidomide similar to rituximab/chemotherapy for follicular lymphoma
Although the efficacy was similar, safety differed between the two regimens.
News
FDA approves ibrutinib with rituximab in Waldenström’s macroglobulinemia
Ibrutinib is already approved as a single agent in Waldenstrom’s macroglobulinemia.
Article
Make The Diagnosis - September 2018
A 75-year-old man presented with asymptomatic annular plaques on both arms, thighs, abdomen, and buttocks, present for several months.
From the Journals
New chronic lymphocytic leukemia guidelines from the UK
The updated guidelines call for assessing TP53 mutations and deletions before each line of therapy.
From the Journals
Insurance is a matter of life or death for lymphoma patients
Improving patient access to affordable private insurance could improve survival outcomes for patients with follicular lymphoma.